RhTFAM treatment stimulates mitochondrial oxidative metabolism and improves memory in aged mice

Ravindar R Thomas1, Shaharyar M Khan, Rafal M Smigrodzki

  • 1Parkinson's Disease Center, Virginia Commonwealth University, Richmond, VA 23298, USA.

Aging
|October 19, 2012
PubMed

Insights

Recombinant human mitochondrial transcription factor A (rhTFAM) treatment reversed age-related mitochondrial decline and memory loss in aged mice. This intervention improved brain function and mitochondrial respiration in multiple tissues.

Area of Science:

  • Mitochondrial biology
  • Neuroscience
  • Aging research

Background:

  • Mitochondrial function declines with age in vital tissues like the brain, heart, and skeletal muscle.
  • Even with exercise, aged mice exhibit reduced mitochondrial DNA (mtDNA) copy numbers and gene transcription, alongside diminished mitobiogenesis signaling in the brain and heart.

Purpose of the Study:

  • To investigate the therapeutic potential of recombinant human mitochondrial transcription factor A (rhTFAM) in counteracting age-related mitochondrial dysfunction and cognitive decline.
  • To assess the impact of rhTFAM treatment on mitochondrial respiration, gene expression, and key signaling pathways in aged mice.

Main Methods:

  • Aged mice were administered weekly intravenous injections of rhTFAM for one month.
  • Mitochondrial respiration, gene transcription (POLRMT), mitobiogenesis signaling (PGC-1 alpha), oxidative stress markers, and levels of brain-derived neurotrophic factor (BDNF) and synapsin were measured.
  • Cognitive function was evaluated using the Morris water maze test.
  • Microarray analysis was performed on brain tissue.

Main Results:

  • rhTFAM treatment significantly enhanced mitochondrial respiration in the brain, heart, and skeletal muscle.
  • The treatment increased POLRMT expression and mtDNA gene transcription in the brain, and boosted PGC-1 alpha signaling in the heart.
  • rhTFAM reduced oxidative stress in the brain, improved memory performance, and elevated BDNF and synapsin levels.
  • Microarray analysis revealed coordinated gene expression patterns in rhTFAM-treated aged brains.

Conclusions:

  • rhTFAM effectively reverses age-related memory impairments linked to mitochondrial energy deficits.
  • The treatment enhances mitochondrial function and increases levels of crucial memory-associated proteins in the brain.
  • rhTFAM demonstrates potential as a therapeutic agent for age-related cognitive decline and mitochondrial dysfunction.